EP1924296A1 - Materiau de bandage a principes actifs - Google Patents

Materiau de bandage a principes actifs

Info

Publication number
EP1924296A1
EP1924296A1 EP06778096A EP06778096A EP1924296A1 EP 1924296 A1 EP1924296 A1 EP 1924296A1 EP 06778096 A EP06778096 A EP 06778096A EP 06778096 A EP06778096 A EP 06778096A EP 1924296 A1 EP1924296 A1 EP 1924296A1
Authority
EP
European Patent Office
Prior art keywords
dressing material
dressing
active ingredient
material according
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06778096A
Other languages
German (de)
English (en)
Other versions
EP1924296B1 (fr
Inventor
Sabine Hohmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP06778096A priority Critical patent/EP1924296B1/fr
Publication of EP1924296A1 publication Critical patent/EP1924296A1/fr
Application granted granted Critical
Publication of EP1924296B1 publication Critical patent/EP1924296B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

Definitions

  • the present invention relates to a bandage material comprising a carrier material and at least one active ingredient each of Arnica montana, Rhus toxicodendron and Ruta graveolens. Furthermore, the invention relates to a medicament comprising this dressing material and the use of this dressing material for the manufacture of a medicament for the treatment of diseases or disorders of the musculoskeletal system.
  • the dressing material is used here as a tape bandage.
  • Injuries of the musculoskeletal system can be treated by partial or complete immobilization of the affected parts of the body.
  • the complete rest position eg by plaster bandages
  • a disadvantage of this treatment method is that the affected parts of the body often have to be immobilized over a longer period of time and the type of immobilization, eg plaster bandage, may result in consequential damage to the body parts, such as circulatory disorders, reduced lymphatic drainage or even tissue atrophy.
  • the type of immobilization eg plaster bandage
  • the tape bandage supports and relieves damaged parts, eg of a joint, for movement, allows a functional load to a limited extent and thereby avoids extreme movements, which could possibly lead to further damage to various parts of the joint.
  • Tapes have not only a stabilizing effect as a passive outer shell, but also activate muscle groups on the irritation of mechanoreceptors in the skin and proprioceptors of muscles and tendons.
  • Taped bandages are now an integral part of medical care. Nevertheless, some of the consequential damage mentioned above in connection with bandages that cause a complete immobilization of the body part can also occur with tapes. These include, in particular, damage due to insufficient lymphatic drainage, blood supply or tissue atrophy.
  • the invention therefore relates to a bandage material comprising a carrier material and at least one active ingredient each of Arnica montana, Rhus toxicodendron and Ruta graveolens.
  • the present invention further relates to a bandage material comprising a carrier material and at least one active ingredient each of Fos cathaimi, Ruta graveolens and Rhus delavayi.
  • the present invention also relates to dressing materials comprising a carrier material, preferably as described above, and having at least one further active ingredient selected from the group consisting of: (i) active ingredients of Bryonia alba, Bryonia dioica, mixtures of cherry plum blossoms, White Clematis flowers, flowers of gland-bearing bracts, flowers of yellow sunshine and flowers of the Golden Star (commercially available as Rescue Remedy Blend), Hypericum perforatum (St.
  • Diclofenac is a known medicinal product with the chemical name [2- (2,6-dichloroanilino) phenyl] acetic acid sodium salt.
  • Dressing material according to the present invention is a flexible material that can be applied to the skin of the body on damaged parts of the body of the musculoskeletal system.
  • the flexibility of the dressing material should be chosen so that it on the one hand a guided, supported movement of the affected parts of the musculoskeletal system On the other hand, however, it also allows it to be fixed sufficiently to avoid undesired or extreme movements, such as overstretching.
  • the bandage material according to the invention can be constructed from one or more materials.
  • the dressing material comprises at least one carrier material as well as an active ingredient or a combination of active ingredients as described above.
  • the active ingredient may in this case be applied directly to the carrier material or be coupled to an adjuvant which is applied to the carrier material.
  • the dressing material can thus also comprise auxiliaries. Suitable excipients include pharmaceutically acceptable solvents for the active ingredients, substances that affect the elasticity or stiffness of the carrier material, but also substances that are needed for the attachment of the dressing material to the skin, such as adhesives.
  • the dressing material may be in any geometric form. Preferably, it is in the form of a rectangular or round plaster or, more preferably, a rectangular band.
  • the dressing material according to the invention is preferably permeable to air, water-repellent and consists of hypoallergenic materials. By choosing suitable colors, preferably red, blue, yellow, it is also possible to influence the body process and the healing process in an energetic way. As dressing materials, it is also possible according to the invention to use all commercially available plasters, bandages or tape dressings.
  • the term "carrier material” is to be understood as meaning a woven or nonwoven fabric which may be composed of one or more different constituents Suitable materials for the backbone of the support material are known in the art, and more preferably the support comprises a mixture of natural components, preferably cotton or rubber, and synthetic components, preferably acrylic Furthermore, the carrier material should be such that it can enter into a connection either directly or via auxiliaries with the aforementioned active substances or combinations of active ingredients Preferably, the support material will be able to bond with an adhesive as disclosed elsewhere in the specification.
  • the term "at least one active ingredient refers both to isolated active ingredients and to mixtures of active substances.
  • An active ingredient as used herein is a chemical compound that can be obtained from any of the aforementioned plants or a plant part, eg, seeds, leaves or stems thereof.
  • a mixture of active substances in the context of the present invention is a mixture of such chemical compounds.
  • the mixture can be prepared by mixing corresponding individual active ingredients or can be provided by joint extraction of various active substances from the plants or plant components.
  • an active ingredient mixture of in each case Arnica montana, Rhus toxicodendron and Ruta graveolens is obtained by extraction with a solvent consisting of an alcohol and water. For this purpose, first healthy plants are harvested, cleaned and then freshly minced.
  • the comminuted plant porridge is then mixed with the solvents and preferably incubated in the dark, so that the active ingredients can be dissolved out of the comminuted plant fragments by the solvent.
  • Subsequent separation of the comminuted plant fragments from the solvent active substance mixture now yields a urea extract.
  • the separation can be carried out for example by filtration, sedimentation or centrifugation.
  • the urea extract is recovered by filtration.
  • the solvent used is preferably 90% alcohol and 10% water. Most preferably, the alcohol is ethanol. Details of the active ingredient formulation and preparation of the active ingredients which are to be used in the context of the present invention can be found in the "German Homeopathic Pharmacopoeia", Schwabe, Leipzig, 1901, (HAB).
  • Extracts of Arnica montana are preferably obtained from the dried subterranean portions of the plant or the flowering aboveground portions according to HAB rules 4a and 17. Extracts from Rhus toxicodendron are preferably obtained from young, not yet lignified sprouts according to rules 2a and Extracts of Ruta graveolens are preferably obtained from the fresh, aerial parts at the flowering time according to rules 3a and 7 of HAB
  • the urea extract prepared by the methods described above is preferably used as dilute extract in the dressing material according to the invention In this case also an alcohol water mixture, preferably as described above, is used.
  • the diluted extract is preferably prepared by sputtering as described in the HAB.
  • active ingredients that can not be dissolved in alcohol distilled water from the raw material (eg plant leaves), first to 3. / 4. Potency be triturated (triturated).
  • the raw material per potency step is triturated 3 x with milk sugar in a mortar and patted, the ratio between raw material and milk sugar should be about 1: 100.
  • the extracts or triturations described above are preferably formulated for topical application.
  • the active substances from the plants or plant constituents of Fos cathaimi, Rhus Delavayi, Bryonia alba, Bryonia dioica, St. John's wort, Apis melifica, Calendula, Agaricus muscarius, Anacardium Orientale, Lendium palustris, Bellis perennsis and Hamamelis virginica can also be obtained according to the regulations HAB.
  • active substances from Bryonia alba or dioica can be obtained according to Rule 2a of the HAB.
  • Active substances from Agaricus muscarius can preferably be obtained according to Rule 3 a of the HAB.
  • Active substances from Apis melifica can preferably be obtained according to Rule 4b of the HAB.
  • the active compounds and active ingredient mixtures are formulated as ointments or creams.
  • the ointments or creams preferably also contain wool wax, wool wax alcohol ointment (consisting of cetylstearyl alcohol, wool wax alcohols and white visilin), thick paraffin and water.
  • the ointments contain the extract or the trituration with the active ingredients in a concentration of 5-20% (w / w), preferably 10% (w / w).
  • the aforementioned extracts or triturations may also be applied to the carrier material in any other form suitable for local administration, e.g. as a gel. However, it is a prerequisite that this form of administration allows a bioavailability of the active ingredients in local, dermal administration.
  • a bandage material comprising the abovementioned constituents has the therapeutic advantages of a
  • a stabilization of the damaged structure below Maintaining good mobility, avoiding muscle atrophy and a therapy-promoting influence of skin and pain receptors, muscle and muscle attachments and the capsule and the ligament apparatus causes.
  • Parts of the musculoskeletal system such as muscular pain syndromes, muscle cramps, joint pain and joint sprains, tendon and ligament disorders, rheumatic complaints, bruises, overstretching, torn muscle fibers, ligament ruptures, strains, recent injuries with severe hematomas, finger compression, ski thumbs, tennis and golf elbow Inpigmentyndrome, insertion endopathies, abductor injuries, knee joint effusions, knee joint complaints, Achilles tendon complaints, heel spurs,
  • Ankle pain fore and midfoot pain (longitudinal and transverse arch), wrist discomfort, cervical spine, thoracic spine or
  • the at least one Arnica montana active ingredient is a dilute extract consisting of a part extract of 10 12 parts of a pharmaceutically acceptable solvent, preferably an alcohol-water mixture as described above.
  • a dilute extract is also referred to in the art as Arnica Dl 2 and is commercially available.
  • the at least one Rhus toxicodendron active ingredient is a dilute extract consisting of a part extract of 10 12 parts of a pharmaceutically acceptable solvent, preferably an ethanol-water mixture as described above.
  • a dilute extract is also referred to in the art as Rhus toxicodendron D12 and is commercially available.
  • the at least one Ruta graveolens active ingredient is a dilute extract consisting of a part extract of 10 12 parts of a pharmaceutically acceptable solvent, preferably an ethanol-water mixture as described above.
  • a dilute extract is also referred to in the art as Ruta graveolens Dl 2 and is commercially available.
  • this has an adhesive for fastening the dressing material to the skin.
  • adhesives in the sense of the present invention can be agents which impart a reversible bond between the skin and the dressing material, These adhesives are preferably adhesives. These adhesives are preferably skin-friendly and do not otherwise cause any body reactions, such as contact allergies Suitable adhesives for dressings, such as patches or tapes, are well known in the art
  • the dressing may be soaked with, or preferably one-sidedly, coated with the adhesive Preferably, the dressing is not completely provided with the adhesive.
  • the adhesive is applied along the boundaries of rhombic surfaces (102), preferably in the form of splints (101), so that the diamond surfaces of the diamonds formed by the boundaries remain free of adhesive.
  • a corresponding dressing material is shown in FIG.
  • the diamond surfaces are then provided with the active ingredients or mixtures of active ingredients.
  • the dressing material may in this case be impregnated with solutions of the corresponding active ingredients or coated therewith, with a coating being preferred.
  • the adhesive is applied flat to the carrier material.
  • Active ingredients are preferably introduced directly into a suitable adhesive before it is applied to the carrier material.
  • suitable adhesives containing the pharmaceutical are preferably introduced directly into a suitable adhesive before it is applied to the carrier material.
  • the active compounds or mixtures of active substances can be applied subsequently, for example as a film, to an adhesive already applied to the carrier material.
  • this bandage can be stretched up to 95% along a first axis (110).
  • the course of the first axis of the dressing material is shown in FIG.
  • the first axis according to the invention, the longitudinal axis of the dressing material which is characterized in that applied with bandage material parallel to an imaginary axis along the skin surface and, if a dressing material with a rectangular shape, for example, a band is used as a dressing material, parallel extends to the longer of the side surfaces of the rectangle.
  • the bandage material can be stretched along a second axis (120) by at most 5%.
  • the second axis is the transverse axis of the dressing material, characterized in that, with the dressing material applied, parallel to an imaginary axis along the skin surface and, if a dressing material of rectangular shape, e.g. a band, as dressing material is used, runs parallel to the shorter of the side surfaces of the rectangle.
  • the carrier material has a first carrier material (201) which is to be brought into contact with the skin and a second carrier material (202) for the outside of the bandage.
  • the first support material (201) comprises zinc oxide, rubber and acrylic, with zinc oxide preferably in 1 to 10%, particularly preferably in 5% (w / w), rubber preferably in 1 to 10%, particularly preferably 5% (w / w ) and acrylic is preferably present in 80 to 98%, more preferably 90% (w / w).
  • the second carrier material (202) is preferably cotton, more preferably pure cotton (100%). A preferred carrier material according to the invention is shown in FIG. 2 and described in the exemplary embodiment.
  • the invention also relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a dressing material according to the invention as described above.
  • the dressing material is sterile packaged in the drug formulation.
  • the bandage material is preferably provided rolled up on a roll as a medicament.
  • the dosage of the agents comprised by the dressing material has been previously described.
  • the drug is so formulated that it can be used as a tape bandage.
  • a rectangular band of bandage material preferably 5 to 15 meters long, most preferably 10 meters long, is rolled up.
  • the invention relates to the use of a dressing material according to the invention as described above for the manufacture of a medicament for the treatment of disorders or disorders of the musculoskeletal system, preferably muscular pain syndrome, muscle cramps, joint pain and joint sprains, tendon and ligament disorders, rheumatic complaints, bruises, overstretching, torn muscle fibers, Ligament rupture, strains, recent injuries with pronounced hematomas, finger compresses, ski thumbs, tennis and golf elbow, impingement syndrome, insertion endopathy, adductor injuries, knee joint effusions, knee joint complaints, Achilles tendon complaints,
  • disorders or disorders of the musculoskeletal system preferably muscular pain syndrome, muscle cramps, joint pain and joint sprains, tendon and ligament disorders, rheumatic complaints, bruises, overstretching, torn muscle fibers, Ligament rupture, strains, recent injuries with pronounced hematomas, finger compresses, ski thumbs, tennis and golf elbow, impingement syndrome,
  • the bandage material is preferably used here as a tape bandage.
  • FIG. 1 shows a view of the skin contact surface of a carrier material according to the invention, wherein boundaries of the rhombic surfaces (101) to be provided with adhesive, the adhesive-free diamond surfaces (102) and the first (longitudinal) axis (110) and the second (transverse) axis (120).
  • Figure 2 The figure shows a cross section through an inventive
  • a carrier material consisting of a first carrier material (201) and a second carrier material (202).
  • the first carrier material (201) should in this case be brought into contact with the skin surface (203).
  • Example 1 Tape Banding Material An approximately 10 m long ribbon of 4.5 cm width consists of a surface material and a skin-side applied material.
  • the surface material is 100% cotton.
  • the skin-side material consists of 5% zinc oxide, 5% rubber and 90% acrylic.
  • An adhesive is applied to the skin side material in strips, the strips being mounted to define diamond shaped surfaces.
  • dilute extracts of Arnica montana, Rhus toxicodendron and Ruta graveolens are applied. The extracts are Arnica D 12, Rhus toxicodendron Dl 2 and Ruta graveolens D12.
  • the dressing material is processed so that it is permeable to air and water repellent.
  • the bandage allows 95% longitudinal stretch and 5% lateral stretch.
  • the substances used for the dressing material are hypoallergenic.
  • the bandage is in the colors red, blue, yellow.
  • the bandage material is used as a tape bandage for injuries and disorders of the musculoskeletal system. Very good results have been achieved on several occasions. In particular, the lymphatic drainage and a better blood supply to the affected parts of the musculoskeletal system could be achieved and muscle atrophy can be avoided.
  • Diagnosis partial rupture was detected with the help of an ultrasound examination previous therapy: Adimedschuh with heel wedges for 4-6 weeks (within this time wedge change to the neutral-zero position of the ankle joint)
  • Patient complains weeks after the healing phase, that the foot was thicker, about morning pain onset and instability feeling.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Materials Engineering (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06778096A 2005-09-13 2006-08-01 Materiau de bandage a principes actifs Active EP1924296B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06778096A EP1924296B1 (fr) 2005-09-13 2006-08-01 Materiau de bandage a principes actifs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05019854 2005-09-13
EP06778096A EP1924296B1 (fr) 2005-09-13 2006-08-01 Materiau de bandage a principes actifs
PCT/EP2006/064887 WO2007031364A1 (fr) 2005-09-13 2006-08-01 Materiau de bandage a principes actifs

Publications (2)

Publication Number Publication Date
EP1924296A1 true EP1924296A1 (fr) 2008-05-28
EP1924296B1 EP1924296B1 (fr) 2009-02-18

Family

ID=37685148

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06778096A Active EP1924296B1 (fr) 2005-09-13 2006-08-01 Materiau de bandage a principes actifs

Country Status (5)

Country Link
US (1) US20100233247A1 (fr)
EP (1) EP1924296B1 (fr)
AT (1) ATE422905T1 (fr)
DE (1) DE502006002907D1 (fr)
WO (1) WO2007031364A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788996A1 (fr) 2019-09-09 2021-03-10 Aktimed GmbH Matière pour pansement

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007023021A1 (de) * 2007-03-26 2008-10-02 Angelika-Regine Dr. med. Dietz Therapeutisches Pflaster für Trigger- und Akupunkturpunkte sowie zur Meridiantherapie
CN102652791B (zh) * 2011-07-25 2014-04-16 长春康彼达科技有限公司 一种具有抗肝纤维化作用的药物组合物及制备方法
EP2702984A1 (fr) * 2012-08-27 2014-03-05 MSF Medizinische Sportwerke Frankfurt GmbH Pansement avec agent actif pour le traitement de symptômes locaux
US10441473B1 (en) * 2014-03-24 2019-10-15 Charise Marie Vacca Taping method for inhibition of skeletal muscle tone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
JPH07500751A (ja) * 1991-11-06 1995-01-26 ビオダーム・インコーポレイテツド 密封包帯材及びアプリケーター
US5397298A (en) * 1992-09-09 1995-03-14 Sherwood Medical Company Elastic bandaging material
CA2092581C (fr) * 1992-12-22 2003-10-14 Judith K. Faass Materiau composite compressible, elastique, non-tisse et autocollant
US6630238B2 (en) * 1995-02-16 2003-10-07 3M Innovative Properties Company Blended pressure-sensitive adhesives
DE19738855C2 (de) * 1997-09-05 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht
US6896897B2 (en) * 1999-07-23 2005-05-24 Alwyn Company, Inc. Flexible applicator for applying oil-in-water emulsion with improved stability
AU2004222357C1 (en) * 2003-03-14 2009-11-19 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammation
US20060029654A1 (en) * 2004-08-04 2006-02-09 Cassel R D Analgesic patch for sports injury rehabilitation medicine and method to alleviate pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007031364A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3788996A1 (fr) 2019-09-09 2021-03-10 Aktimed GmbH Matière pour pansement

Also Published As

Publication number Publication date
US20100233247A1 (en) 2010-09-16
WO2007031364A1 (fr) 2007-03-22
ATE422905T1 (de) 2009-03-15
EP1924296B1 (fr) 2009-02-18
DE502006002907D1 (de) 2009-04-02

Similar Documents

Publication Publication Date Title
EA018425B1 (ru) Фармацевтический, дезинфицирующий или консервирующий экстракт пажитника сенного (trigonella foenum-graecum), способ его получения и применение экстракта
US20060269569A1 (en) Universal antioncotic and pain relieving ointment
CN104257970B (zh) 一种外用跌打药膏
DE3014524A1 (de) Wundheilmittel
EP1924296B1 (fr) Materiau de bandage a principes actifs
CN110292602A (zh) 一种复方五黄烧伤油配方及其制备方法
Carneiro et al. Topical phenytoin versus EUSOL in the treatment of non-malignant chronic leg ulcers
DE19654468C1 (de) Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
DE69927154T2 (de) Vorrichtung und verfahren zur behandlung von erektionsstörungen
JPH08511283A (ja) 皮膚再生および治療用製造物、その製造方法およびその使用
KR20130120375A (ko) 피부 궤양을 치료 및/또는 예방하기 위한 성분의 키트
DE19681207B4 (de) Therapeutische Verwendung von Rubidiumionen und Zubereitungen
US7205009B2 (en) Composition for treating hair and scalp and method for preparing same
DE602005004030T2 (de) ZUSAMMENSETZUNG UMFASSEND NEEMÖL UND EXTRAKT VON HYPERICUM MIT HELLENDEN, ABWEISENDEN UND BIOZIDEN EIGENSCHAFTEN ZUR BEHANDLUNG ÄUßERER WUNDEN
EP0699443B1 (fr) Composition pour la peau contenant du sureau
US20240269088A1 (en) Pain relief patch
RU2416425C1 (ru) Масло противопролежневое
DE10340428B4 (de) Opioides Analgetikum enthaltende transdermale Formulierung
CN101703667B (zh) 一种竭红跌打药剂及其制备方法
RU2337702C2 (ru) Бальзам "гайсановой", обладающий ранозаживляющим, противовоспалительным и противоожоговым действием
DE102006001162A1 (de) Pflasterabdeckung bei atopischer Dermatitis
KR101034212B1 (ko) 소나무껍질추출물을 함유한 패치 제제
DE102005061246A1 (de) Präparate mit niedermolekularen Substanzen aus Dipteren zur Behandlung von Wunden
CN112741863A (zh) 一种治疗皮肤创伤的药物及其制备方法
KR20220144070A (ko) 계란 껍데기 분말을 유효 성분으로 함유하는 화상 치료용 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080319

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REF Corresponds to:

Ref document number: 502006002907

Country of ref document: DE

Date of ref document: 20090402

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090529

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090618

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090518

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090727

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20091119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090518

BERE Be: lapsed

Owner name: HOHMANN, SABINE

Effective date: 20090831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090218

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230824

Year of fee payment: 18

Ref country code: CH

Payment date: 20230902

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230821

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240829

Year of fee payment: 19